Search Results - "Park, Steven"

Understanding Echinocandin Resistance in the Emerging Pathogen Candida auris by Kordalewska, Milena, Lee, Annie, Park, Steven, Berrio, Indira, Chowdhary, Anuradha, Zhao, Yanan, Perlin, David S

“…has simultaneously emerged on five continents as a fungal pathogen causing nosocomial outbreaks. The challenges in the treatment of infections are the variable…”
Get full text

Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study by Younes, Anas, Dr, Connors, Joseph M, Prof, Park, Steven I, MD, Fanale, Michelle, MD, O'Meara, Megan M, MD, Hunder, Naomi N, MD, Huebner, Dirk, MD, Ansell, Stephen M, Prof

“…Summary Background Roughly 70–80% of patients with advanced stage Hodgkin's lymphoma are cured with various first-line and second-line treatments, including…”
Get full text

Anti-CD30 CAR-T Cell Therapy in Relapsed and Refractory Hodgkin Lymphoma by Ramos, Carlos A, Grover, Natalie S, Beaven, Anne W, Lulla, Premal D, Wu, Meng-Fen, Ivanova, Anastasia, Wang, Tao, Shea, Thomas C, Rooney, Cliona M, Dittus, Christopher, Park, Steven I, Gee, Adrian P, Eldridge, Paul W, McKay, Kathryn L, Mehta, Birju, Cheng, Catherine J, Buchanan, Faith B, Grilley, Bambi J, Morrison, Kaitlin, Brenner, Malcolm K, Serody, Jonathan S, Dotti, Gianpietro, Heslop, Helen E, Savoldo, Barbara

“…Chimeric antigen receptor (CAR) T-cell therapy of B-cell malignancies has proved to be effective. We show how the same approach of CAR T cells specific for…”
Get full text

Trispecific natural killer cell nanoengagers for targeted chemoimmunotherapy by Au, Kin Man, Park, Steven I, Wang, Andrew Z

“…Activation of the innate immune system and natural killer (NK) cells has been a key effort in cancer immunotherapy research. Here, we report a…”
Get full text

Equal access to care and nurse navigation leads to equitable outcomes for minorities with aggressive large B-cell lymphoma by Hu, Bei, Boselli, Danielle, Pye, Lisa M, Chen, Tommy, Bose, Rupali, Symanowski, James T, Blackley, Kris, Moyo, Tamara K, Jacobs, Ryan, Park, Steven I, Soni, Amy, Avalos, Belinda R, Copelan, Edward A, Raghavan, Derek, Ghosh, Nilanjan

“…Aggressive large B-cell lymphomas (LBCLs) are curable, but previous studies have shown inferior outcomes in minorities. Nurse navigation programs can improve…”
Get full text

Pretargeted delivery of PI3K/mTOR small-molecule inhibitor-loaded nanoparticles for treatment of non-Hodgkin's lymphoma by Au, Kin Man, Wang, Andrew Z, Park, Steven I

“…Overactivation of the PI3K/mTOR signaling has been identified in non-Hodgkin's lymphoma. BEZ235 is an effective dual PI3K/mTOR inhibitor, but it was withdrawn…”
Get full text

Rapid and quantitative detection of SARS-CoV-2 specific IgG for convalescent serum evaluation by Tan, Xiaotian, Krel, Mila, Dolgov, Enriko, Park, Steven, Li, Xuzhou, Wu, Weishu, Sun, Yun-Lu, Zhang, Jie, Khaing Oo, Maung Kyaw, Perlin, David S., Fan, Xudong

“…Convalescent serum with a high abundance of neutralization IgG is a promising therapeutic agent for rescuing COVID-19 patients in the critical stage. Knowing…”
Get full text

Bortezomib in combination with dose-adjusted EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin) induces long-term survival in patients with plasmablastic lymphoma: a retrospective analysis by Dittus, Christopher, Grover, Natalie, Ellsworth, Steven, Tan, Xianming, Park, Steven I.

“…Plasmablastic lymphoma (PBL) is a rare and aggressive form of B-cell non-Hodgkin lymphoma. This subtype of lymphoma has a post-germinal center cell-of-origin…”
Get full text

Correlating Echinocandin MIC and Kinetic Inhibition of fks1 Mutant Glucan Synthases for Candida albicans: Implications for Interpretive Breakpoints by GARCIA-EFFRON, Guillermo, PARK, Steven, PERLIN, David S

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Cause‐specific mortality among Medicare beneficiaries with newly diagnosed non‐Hodgkin lymphoma subtypes by Hester, Laura L., Park, Steven I., Wood, William A., Stürmer, Til, Brookhart, M. Alan, Lund, Jennifer L.

“…Background As the US population ages and non‐Hodgkin lymphoma (NHL)–specific mortality declines, deaths from causes other than NHL will become increasingly…”
Get full text

Positron Emission Tomography-Directed Therapy for Patients With Limited-Stage Diffuse Large B-Cell Lymphoma: Results of Intergroup National Clinical Trials Network Study S1001 by Persky, Daniel O, Li, Hongli, Stephens, Deborah M, Park, Steven I, Bartlett, Nancy L, Swinnen, Lode J, Barr, Paul M, Winegarden, 3rd, Jerome D, Constine, Louis S, Fitzgerald, Thomas J, Leonard, John P, Kahl, Brad S, LeBlanc, Michael L, Song, Joo Y, Fisher, Richard I, Rimsza, Lisa M, Smith, Sonali M, Miller, Thomas P, Friedberg, Jonathan W

“…Diffuse large B-cell lymphoma (DLBCL) presents as a limited-stage disease in 25% to 30% of patients, with better overall survival (OS) than that for…”
Get full text

Gravitational forces, negative pressure and facial structure in the genesis of airway dysfunction during sleep: a review of the paradigm by Stupak, Howard D., Park, Steven Y.

“…The recent and distant literature has extensive discussion of how sleep apnea, adeno-tonsillar growth, and facial structural deformity are related…”
Get full text

Mogamulizumab: An Anti-CC Chemokine Receptor 4 Antibody for T-Cell Lymphomas by Moore, Donald C., Elmes, Joseph B., Shibu, Priscila A., Larck, Chris, Park, Steven I.

“…Objective: To review the pharmacology, pharmacokinetics, efficacy, safety, dosing, and administration of mogamulizumab for the treatment of T-cell lymphomas…”
Get full text

The role of autologous stem cell transplantation in patients with nodal peripheral T‐cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study by Park, Steven I., Horwitz, Steven M., Foss, Francine M., Pinter‐Brown, Lauren C., Carson, Kenneth R., Rosen, Steven T., Pro, Barbara, Hsi, Eric D., Federico, Massimo, Gisselbrecht, Christian, Schwartz, Marc, Bellm, Lisa A., Acosta, Mark, Advani, Ranjana H., Feldman, Tatyana, Lechowicz, Mary Jo, Smith, Sonali M., Lansigan, Frederick, Tulpule, Anil, Craig, Michael D., Greer, John P., Kahl, Brad S., Leach, Joseph W., Morganstein, Neil, Casulo, Carla, Shustov, Andrei R.

“…Background The role of autologous stem cell transplantation (ASCT) in the first complete remission (CR1) of peripheral T‐cell lymphomas (PTCLs) is not well…”
Get full text

Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry by Lansigan, Frederick, Horwitz, Steven M, Pinter-Brown, Lauren C, Rosen, Steven T, Pro, Barbara, Hsi, Eric D, Federico, Massimo, Gisselbrecht, Christian, Schwartz, Marc, Bellm, Lisa A, Acosta, Mark, Shustov, Andrei R, Advani, Ranjana H, Feldman, Tatyana, Lechowicz, Mary Jo, Smith, Sonali M, Tulpule, Anil, Craig, Michael D, Greer, John P, Kahl, Brad S, Leach, Joseph W, Morganstein, Neil, Casulo, Carla, Park, Steven I, Foss, Francine M

“…Outcomes for patients with peripheral T-cell lymphoma (PTCL) who fail to achieve complete response (CR) or relapse after front-line therapy are poor with lack…”
Get more information

Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma by Connors, Joseph M., Ansell, Stephen M., Fanale, Michelle, Park, Steven I., Younes, Anas

“…Publisher's Note: There is an Inside Blood Commentary on this article in this issue…”
Get full text

Effect of Candida glabrata FKS1 and FKS2 Mutations on Echinocandin Sensitivity and Kinetics of 1,3-β-d-Glucan Synthase: Implication for the Existing Susceptibility Breakpoint by GARCIA-EFFRON, Guillermo, LEE, Samuel, PARK, Steven, CLEARY, John D, PERLIN, David S

“…Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit…”
Get full text

Discovery of MRSA active antibiotics using primary sequence from the human microbiome by Chu, John, Vila-Farres, Xavier, Inoyama, Daigo, Ternei, Melinda, Cohen, Louis J, Gordon, Emma A, Reddy, Boojala Vijay B, Charlop-Powers, Zachary, Zebroski, Henry A, Gallardo-Macias, Ricardo, Jaskowski, Mark, Satish, Shruthi, Park, Steven, Perlin, David S, Freundlich, Joel S, Brady, Sean F

“…The synthetic bioinformatic natural products (syn-BNPs) approach identifies putative natural products that are validated directly by independent synthesis. Its…”
Get full text

A phase 1 trial of ibrutinib plus palbociclib in previously treated mantle cell lymphoma by Martin, Peter, Bartlett, Nancy L., Blum, Kristie A., Park, Steven, Maddocks, Kami, Ruan, Jia, Ridling, LeAnn, Dittus, Christopher, Chen, Zhengming, Huang, Xiangao, Inghirami, Giorgio, DiLiberto, Maurizio, Chen-Kiang, Selina, Leonard, John P.

“…Single-agent ibrutinib is active in patients with previously treated mantle cell lymphoma (MCL); however, nearly half of all patients experience treatment…”
Get full text

Bespoke Pretargeted Nanoradioimmunotherapy for the Treatment of Non-Hodgkin Lymphoma by Au, Kin Man, Tripathy, Ashutosh, Lin, Carolina Pe-I, Wagner, Kyle, Hong, Seungpyo, Wang, Andrew Z, Park, Steven I

“…Non-Hodgkin lymphoma (NHL) is one of the most common types of hematologic malignancies. Pretargeted radioimmunotherapy (PRIT), the sequential administration of…”
Get full text